Activation of p38 mitogen-activated protein kinase in Gaucher's disease

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Kitatani, Kazuyuki ^a,b   Wada, Masayuki ^c   Perry, David ^d   Usui, Toshinori ^a   Sun, Ying ^e,f   Obeid, Lina M ^c,g,h   Yaegashi, Nobuo ^a,b   Grabowski, Gregory A ^e,f   Hannun, Yusuf A ^c,h  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Stony Brook School of Dental Medicine   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g Northport Veterans Affairs Hospital   (United States)

^h STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; IL6 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FIBROBLAST; GAUCHER DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIVER; LUNG PARENCHYMA; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL LINE; DISEASE MODEL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTANT MOUSE STRAIN; PATHOLOGY;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FIBROBLASTS; GAUCHER DISEASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; HUMANS; INTERLEUKIN-6; MICE; MICE, MUTANT STRAINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; UP-REGULATION;

EID: 84943329780     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136633     Document Type: Article

References (33)

1. Brady RO. (1978) Sphingolipidoses, Annu Rev Biochem. 47, 687-713.
2. Dinur T, Osiecki KM, Legler G, Gatt S, Desnick RJ, Grabowski GA (1986) Human acid beta-glucosidase: isolation and amino acid sequence of a peptide containing the catalytic site, Proceedings of the National Academy of Sciences of the United States of America. 83, 1660-4.
3. Grabowski GA (1993) Gaucher disease. Enzymology, genetics, and treatment, Adv Hum Genet. 21, 377-441.
4. Futerman AH, van Meer G (2004) The cell biology of lysosomal storage disorders, Nat Rev Mol Cell Biol. 5, 554-65.
5. Mistry PK, Cox TM (1993) The glucocerebrosidase locus in Gaucher's disease: molecular analysis of a lysosomal enzyme, Journal of medical genetics. 30, 889-94.
6. Grabowski GA, Hopkin RJ (2003) Enzyme therapy for lysosomal storage disease: principles, practice, and prospects, Annual review of genomics and human genetics. 4, 403-36.
7. Jmoudiak M, Futerman AH (2005) Gaucher disease: pathological mechanisms and modern management, British journal of haematology. 129, 178-88.
8. Vitner EB, Farfel-Becker T, Eilam R, Biton I, Futerman AH (2012) Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease, Brain. 135, 1724-35.
9. Pandey MK, Rani R., Zhang W, Setchell K, Grabowski GA (2012) Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease, Molecular genetics and metabolism. 106, 310-22.
10. Hollak CE, Evers L, Aerts JM, van Oers MH (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease, Blood Cells Mol Dis. 23, 201-12.
11. Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, Yatziv S. (1999) Cytokines in Gaucher's disease, Eur Cytokine Netw. 10, 205-10.
12. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM (1997) Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10, QJM. 90, 19-25.
13. Mizukami H, Mi Y, Wada R, Kono M, Yamashita T, Liu Y, et al. (2002) Systemic inflammation in glucocerebrosidasedeficient mice with minimal glucosylceramide storage, J Clin Invest. 109, 1215-21.
14. Jeyakumar M, Smith DA, Williams IM, Borja MC, Neville DC, Butters TD, et al. (2004) NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin, Annals of neurology. 56, 642-9.
15. Smith D, Wallom KL, Williams IM, Jeyakumar M, Platt FM (2009) Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1, Neurobiology of disease. 36, 242-51.
16. Kitatani K, Sheldon K, Anelli V, Jenkins RW, Sun Y, Grabowski GA, et al. (2009) Acid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an antiinflammatory lipid, The Journal of biological chemistry. 284, 12979-88.
17. Kitatani K, Sheldon K, Rajagopalan V, Anelli V, Jenkins RW, Sun Y, et al. (2009) Involvement of acid beta-glucosidase 1 in the salvage pathway of ceramide formation, The Journal of biological chemistry. 284, 12972-8.
18. Cuenda A, Rousseau S (2007) p38 MAP-kinases pathway regulation, function and role in human diseases, Biochimica et biophysica acta. 1773, 1358-75.
19. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA (2009) p38 (MAPK): stress responses from molecular mechanisms to therapeutics, Trends in molecular medicine. 15, 369-79.
20. Bachstetter AD, Van Eldik LJ (2010) The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS, Aging and disease. 1, 199-211.
21. Xu YH, Quinn B, Witte D, Grabowski GA (2003) Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease, Am J Pathol. 163, 2093-101.
22. Sun Y, Quinn B, Witte DP, Grabowski GA (2005) Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants, J Lipid Res. 46, 2102-13.
23. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. (1985) Measurement of protein using bicinchoninic acid, Analytical biochemistry. 150, 76-85.
24. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, et al. (1993) Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6, Proceedings of the National Academy of Sciences of the United States of America. 90, 10061-5.
25. Kitatani K, Idkowiak-Baldys J, Bielawski J, Taha TA, Jenkins RW, Senkal CE, et al. (2006) Protein kinase C-induced activation of a ceramide/protein phosphatase 1 pathway leading to dephosphorylation of p38 MAPK, The Journal of biological chemistry. 281, 36793-802.
26. Sun Y, Ran H, Liou B, Quinn B, Zamzow M, Zhang W, et al. (2011) Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse, PLoS One. 6, e19037.
27. Kumar S, Boehm J, Lee JC (2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases, Nat Rev Drug Discov. 2, 717-26.
28. Cuadrado A, Nebreda AR (2010) Mechanisms and functions of p38 MAPK signalling, The Biochemical journal. 429, 403-17.
29. Dean JL, Sully G, Clark AR, Saklatvala J (2004) The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation, Cellular signalling. 16, 1113-21.
30. Olson JM, Hallahan AR (2004) p38 MAP kinase: a convergence point in cancer therapy, Trends in molecular medicine. 10, 125-9.
31. Probert L, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoulou L, Kollias G. (1997) TNF-alpha transgenic and knockout models of CNS inflammation and degeneration, Journal of neuroimmunology. 72, 137-41.
32. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G (1995) Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha, Proceedings of the National Academy of Sciences of the United States of America. 92, 11294-8.
33. Munoz-Fernandez MA, Fresno M (1998) The role of tumour necrosis factor, interleukin 6, interferongamma and inducible nitric oxide synthase in the development and pathology of the nervous system, Progress in neurobiology. 56, 307-40.